Abiraterone With Dalpiciclib in Salivary Gland Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of abiraterone combined with dalpiciclib in recurrent/metastatic salivary gland carcinoma patients with AR positive and Her-2 negative. The participants would receive abiraterone combined with dalpiciclib until termination criteria are met.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony histopatologicznie rak ślinianek głowy i szyi, zaawansowany lub nawrotowy, bez możliwości chirurgii lub radioterapii
- •Co najmniej jeden zmierzalny guz (≥10 mm)
- •Dodatni wynik testu AR i ujemny wynik testu HER-2 w badaniu mikroskopowym
- •Dostępna próbka tkanki nowotworowej z ostatnich 2 lat
- •Dobry stan ogólny pacjenta (ECOG 0-1)
- •Spodziewana przeżywalność co najmniej 12 tygodni
- •Prawidłowe funkcje narządów (wątroba, nerki, serce, szpik kostny)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Trial contact
Guoxin Ren, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.